Literature DB >> 16815978

ATP and norepinephrine contributions to sympathetic vasoconstriction of tail artery are altered in streptozotocin-diabetic rats.

Lynne Speirs1, Aisling Donnelly, Joanne Lynch, C Norman Scholfield, Christopher Johnson.   

Abstract

Sympathetic vasoconstriction is susceptible to diabetes, but contributions made by purinergic neurotransmission in this state have not been investigated. We aimed to evaluate sympathetic vasoconstriction contributions by ATP and norepinephrine in the tail artery from streptozotocin-diabetic rats by using isometric vascular rings. Tail arteries were isolated from rats made diabetic 3 mo earlier with streptozotocin (diabetic group), age-matched nondiabetic rats (nondiabetic injected), age-matched untreated animals (noninjected normal), and age-matched untreated animals in high glucose control Krebs solution (high glucose control). Responses to KCl (60 mM) or nerve stimulus trains of 1-100 impulses were identical in all groups. Electrical stimulation produced progressively greater contractions with increasing impulse numbers. These were partially reduced by suramin (100 microM, P2 antagonist), NF-279 (1 microM, P2X blocker), and phentolamine (2 microM, alpha-blocker). For purinergic antagonists, blockade was greater in diabetic vessels compared with that in others. No differential effect could be detected for phentolamine between groups. Bath-applied ATP (1 nM-1 mM) and norepinephrine (0.1 nM-100 microM) showed increased potency with diabetic group vessels. Desipramine (1 microM, norepinephrine reuptake inhibitor) potentiated neurally evoked responses in all groups equally and increased sensitivity to exogenous norepinephrine in a similar fashion. Histochemical labeling of sympathetic nerves with neuronal marker protein PGP-9.5 and a sympathetic nerve-specific antibody for tyrosine hydroxylase showed no reduction in diabetic innervation density. We demonstrate, for the first time, changes in contributions of ATP and norepinephrine in sympathetic responses of rat tail artery in diabetes, which cannot be accounted for by axonal degeneration or by changes in norepinephrine reuptake.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16815978     DOI: 10.1152/ajpheart.01298.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

1.  Rho kinase and protein kinase C involvement in vascular smooth muscle myofilament calcium sensitization in arteries from diabetic rats.

Authors:  I V Kizub; O O Pavlova; C D Johnson; A I Soloviev; A V Zholos
Journal:  Br J Pharmacol       Date:  2010-03-09       Impact factor: 8.739

Review 2.  Alteration of purinergic signaling in diabetes: Focus on vascular function.

Authors:  Rui Zhou; Xitong Dang; Randy S Sprague; S Jamal Mustafa; Zhichao Zhou
Journal:  J Mol Cell Cardiol       Date:  2020-02-11       Impact factor: 5.000

3.  Effects of high-fat diet on sympathetic neurotransmission in mesenteric arteries from Dahl salt-sensitive rat.

Authors:  Kibrom M Alula; Rebecca Biltz; Hui Xu; Hannah Garver; Erinn L Laimon-Thomson; Gregory D Fink; James J Galligan
Journal:  Auton Neurosci       Date:  2019-10-31       Impact factor: 3.145

4.  Vascular-dependent effects of elevated glucose on postganglionic sympathetic neurons.

Authors:  Deborah H Damon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-07       Impact factor: 4.733

5.  Increased peripherin in sympathetic axons innervating plantar metatarsal arteries in STZ-induced type I diabetic rats.

Authors:  Niloufer J Johansen; Tony Frugier; Billie Hunne; James A Brock
Journal:  Front Neurosci       Date:  2014-05-07       Impact factor: 4.677

6.  Influence of sildenafil on the purinergic components of nerve-mediated and urothelial ATP release from the bladder of normal and spinal cord injured mice.

Authors:  Basu Chakrabarty; Hiroki Ito; Manuela Ximenes; Nobuyuki Nishikawa; Bahareh Vahabi; Anthony J Kanai; Anthony E Pickering; Marcus J Drake; Christopher H Fry
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.